Congressional Research Service Reports - 4 Matching Results
Search Results
- Follow-On Biologics: Intellectual Property and Innovation Issues
- Biologics, which are sometimes termed biopharmaceuticals or biotechnology drugs, have begun to play an increasingly important role in U.S. health care. Not only are sales of biologics growing rapidly, some experts estimate that in coming years half of all newly approved drugs will result from biotechnology. This report contains information on marketing approval issues, intellectual property issues, and innovation issues as related to biologics.
- Intellectual Property Rights and International Trade
- This report discusses the different kinds of intellectual property rights (IPR); forms of IPR infringement; importance of IPR to the U.S. economy; estimated losses associated with IPR infringement; organizational structure of IPR protection in multilateral, regional, bilateral; U.S. government agencies involved with IPR and trade; and issues for Congress regarding IPR and international trade.
- The Family Entertainment and Copyright Act of 2005
- Intellectual property legislation that came close to enactment during the 108th Congress has been enacted. The Family Entertainment and Copyright Act of 2005 was signed into law on April 27, 2005. Among the issues addressed are unauthorized distribution of pre-release commercial works, the marketing of devices for home use to edit objectionable content from DVDs, the preservation of the nation's film heritage, and use by libraries and archives of "orphan works."
- H.R. 1417: The Copyright Royalty and Distribution Reform Act of 2004
- H.R. 1417, 108th Congress, first session, was introduced on March 25, 2003 and passed by the House on March 3, 2004. If enacted, this bill would make extensive changed to the procedural framework for adjudicating royalty rates for compulsory licenses under the Copyright Act. This report details the background and legislative action on the Copyright Royalty and Distribution Reform Act of 2004.